The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD
心房颤动 - HD 风险调整研究的因素识别
基本信息
- 批准号:8678908
- 负责人:
- 金额:$ 46.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-01 至 2016-05-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAffectAgeAlgorithmsAmericanArrhythmiaAtrial FibrillationBerlinBioinformaticsBiometryBlood PressureC-reactive proteinCalciumCardiovascular systemCaringCathetersCaucasoid RaceCessation of lifeCharacteristicsClinicalComorbidityCoronary heart diseaseDataData SetDatabasesDeltastabDiabetes MellitusDiagnosisDialysis patientsDialysis procedureDigestive System DisordersElderlyElectrocardiogramElectrolytesElectronic Health RecordEnd stage renal failureEnvironmentEthnic OriginExcisionFundingHealthHealth Care CostsHealthcareHeart AtriumHeart RateHeart Valve DiseasesHeart failureHematological DiseaseHemodialysisHemoglobinHispanicsHormonesHospitalizationHypotensionIncidenceInstitutesInsuranceInterventionIntervention StudiesIschemic StrokeKidneyKidney DiseasesLaboratoriesLeadLeftLifeLinkLiquid substanceMaintenanceMeasurementMeasuresMedical RecordsMedicareMedicare claimMethodsMissionModificationMorbidity - disease rateMyocardial InfarctionNutritional statusOutcomeParathyroid glandPatient CarePatient Outcomes AssessmentsPatientsPeripheralPhosphorusPopulationPositioning AttributePotassiumPrevalencePreventiveProteinsProviderQuality of CareQuestionnairesRecurrenceRenal dialysisReportingResearchRiskRisk FactorsSerum AlbuminSerum Calcium LevelShapesSleep Apnea SyndromesSodiumStrokeSystemTestingThromboembolismTimeTreatment FactorUreaUrologic DiseasesVariantWorkbaseclinically relevantcostexperiencehealth care service utilizationhealth related quality of lifehigh riskimprovedindium arsenideinnovationinstrumentinterestlongitudinal databaselow socioeconomic statusmalemodifiable riskmortalitynovelolder patientpatient populationphysical conditioningpoint of carepreventpublic health relevancetreatment durationtrend
项目摘要
DESCRIPTION (provided by applicant): More than 575,000 Americans have end-stage renal disease, and more than 350,000 receive life-saving dialysis treatment. Previous research has demonstrated that patients undergoing hemodialysis, especially those who are older, are at particular risk to have atrial fibrillation. Atrial fibrillation is associated with poor outcomes including high mortality (40% per year). Little is known about fixed and potentially modifiable ris factors for atrial fibrillation in older patients receiving hemodialysis; there is also only scant evidence about these patients' outcomes after their first diagnosis with atrial fibrillation. From
already collected Medicare insurance claims and medical records of a large dialysis provider, we propose to assemble a unique dataset that will provide unprecedented detail about these patients health and the health care they receive. In addition, we will have historical Medicare claims predating these patients' time of dialysis initiation by at least 2 years. Using this unique
database, we will be in the unusual situation to be able to exclude patients who had atrial fibrillation before they started dialysis, and therefore be able to study incident atrial fibrillaton. We are proposing to identify potentially modifiable risk factors for incident atrial fibrillation, ith particular focus on laboratory measurements, vital signs, dialysis treatment- related factors, and dialysis facility practices. We will also launch a comprehensive assessment of the outcomes of patients once they are first diagnosed with atrial fibrillation, in comparison to similar patients who have not developed this arrhythmia. Outcomes of interest will cover all relevant domains: all-cause and cause-specific mortality; morbidity with focus on thromboembolic and hemorrhagic outcomes; patient-reported health-related quality of life outcomes; and health care utilization and cost. These studies will fill gaping holes in the currently available evidence. The perhaps most innovative aim will focus on deriving a prediction algorithm for near-term risk of new atrial fibrillation using the high-dimensional and extremely granular data in our dataset and novel bioinformatic methods. We will then validate the algorithm in a completely different later time period in data from the same provider as well as in another dataset from a different dialysis provider. If our approach proves successful in identifying patients at the highest near-term risk of incident atrial fibrillation, we are then in the position to test intervention studies to reducethe risk of imminent atrial fibrillation and thus avoid longer term sequelae of this arrhythmia in thes vulnerable patients. Findings from the proposed work have the potential to impact and improve the care that patients with end-stage renal disease receive. Our results may improve the quality of care received and, thus, the outcomes of this vulnerable patient population. The aims and scope of work are in full congruence with the mission of the National Institutes of Diabetes and Digestive and Kidney Diseases, and more specifically the Division of Kidney, Urologic, and Hematologic Diseases, which will consider this application for funding.
描述(由申请人提供):超过575,000名美国人患有终末期肾病,超过350,000人接受挽救生命的透析治疗。以前的研究表明,接受血液透析的患者,特别是那些年龄较大的患者,患房颤的风险特别高。房颤与不良结局相关,包括高死亡率(每年40%)。在接受血液透析的老年患者中,关于房颤的固定和潜在可改变的风险因素知之甚少;关于这些患者首次诊断为房颤后的结局也缺乏证据。 从
我们已经收集了一家大型透析提供商的医疗保险索赔和医疗记录,我们建议收集一个独特的数据集,提供有关这些患者健康和他们接受的医疗保健的前所未有的细节。此外,我们将有这些患者透析开始前至少2年的历史医疗保险索赔。利用这种独特的
数据库中,我们将在不寻常的情况下能够排除在开始透析前患有房颤的患者,因此能够研究事件心房颤动。 我们建议识别房颤事件的潜在可改变风险因素,特别关注实验室测量、生命体征、透析治疗相关因素和透析机构实践。我们还将对首次诊断为房颤的患者的结局进行全面评估,并与未发生这种心律失常的类似患者进行比较。关注的结局将涵盖所有相关领域:全因和病因特异性死亡率;关注血栓栓塞和出血结局的发病率;患者报告的健康相关生活质量结局;以及医疗保健利用和成本。这些研究将填补现有证据中的漏洞。也许最具创新性的目标将集中在使用我们数据集中的高维和极细粒度数据以及新的生物信息学方法来推导新的房颤近期风险的预测算法。然后,我们将在来自同一提供者的数据以及来自不同透析提供者的另一个数据集中,在完全不同的后期时间段内验证算法。如果我们的方法被证明成功识别出近期发生房颤风险最高的患者,那么我们就可以对干预研究进行测试,以降低即将发生房颤的风险,从而避免这些脆弱患者发生心律失常的长期后遗症。 这项研究的结果有可能影响和改善终末期肾病患者接受的护理。我们的研究结果可能会提高所接受的护理质量,从而改善这一弱势患者群体的结局。工作的目标和范围与国家糖尿病、消化和肾脏疾病研究所的使命完全一致,更具体地说,与肾脏、泌尿系统和血液系统疾病研究所完全一致,该研究所将考虑这项资助申请。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WOLFGANG CHRISTOPH WINKELMAYER其他文献
WOLFGANG CHRISTOPH WINKELMAYER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WOLFGANG CHRISTOPH WINKELMAYER', 18)}}的其他基金
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD
CKD/ESRD 风险调整研究的心房颤动因素识别
- 批准号:
10542356 - 财政年份:2012
- 资助金额:
$ 46.56万 - 项目类别:
The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD
心房颤动 - HD 风险调整研究的因素识别
- 批准号:
8372215 - 财政年份:2012
- 资助金额:
$ 46.56万 - 项目类别:
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD
CKD/ESRD 风险调整研究的心房颤动因素识别
- 批准号:
10084289 - 财政年份:2012
- 资助金额:
$ 46.56万 - 项目类别:
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD
CKD/ESRD 风险调整研究的心房颤动因素识别
- 批准号:
10319987 - 财政年份:2012
- 资助金额:
$ 46.56万 - 项目类别:
The Atrial Fibrillation-Factor Identification to Risk Modification Study in CKD/ESRD
CKD/ESRD 风险调整研究的心房颤动因素识别
- 批准号:
9885396 - 财政年份:2012
- 资助金额:
$ 46.56万 - 项目类别:
The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD
心房颤动 - HD 风险调整研究的因素识别
- 批准号:
8517713 - 财政年份:2012
- 资助金额:
$ 46.56万 - 项目类别:
2012 ASN Update on Patient Centered Outcomes Research in Kidney Disease
2012 年 ASN 肾脏疾病以患者为中心的结果研究更新
- 批准号:
8458852 - 财政年份:2012
- 资助金额:
$ 46.56万 - 项目类别:
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD
治疗 HD 贫血的新型药物的有效性和安全性比较
- 批准号:
8238024 - 财政年份:2011
- 资助金额:
$ 46.56万 - 项目类别:
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD
治疗 HD 贫血的新型药物的有效性和安全性比较
- 批准号:
8540416 - 财政年份:2011
- 资助金额:
$ 46.56万 - 项目类别:
Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD
治疗 HD 贫血的新型药物的有效性和安全性比较
- 批准号:
9038583 - 财政年份:2011
- 资助金额:
$ 46.56万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 46.56万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 46.56万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 46.56万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 46.56万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 46.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 46.56万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 46.56万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 46.56万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 46.56万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 46.56万 - 项目类别:
Miscellaneous Programs














{{item.name}}会员




